Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 18;19(7(Suppl 6)):21108.
doi: 10.7448/IAS.19.7.21108. eCollection 2016.

Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy

Carlos F Cáceres  1 , Annick Borquez  2 , Jeffrey D Klausner  3   4 , Rachel Baggaley  5 , Chris Beyrer  6
Affiliations

Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy

Carlos F Cáceres et al. J Int AIDS Soc. .

Abstract

Background: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries.

Discussion: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive "combination prevention" programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand.

Conclusions: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers' openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.

Keywords: HIV; acceptability; combination prevention; health systems; implementation science; pre-exposure prophylaxis; program cost; scale-up.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. WHO. Geneva: WHO; 2015. Early release guidelines for the use of ARVs in HIV treatment and prevention.
    1. Volk J, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV pre-exposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3. doi: http://dx.doi.org/10.1093/cid/civ778. - DOI - PMC - PubMed
    1. Statement on PrEP from Community Organisations working on HIV Prevention. [cited 2016 Feb 12]. Available from: www.prepaccess.org.uk.
    1. Cáceres CF, Koechlin F, Goicochea P, Sow PS, O'Reilly K, Mayer KH, et al. The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc. 2015;18(Suppl 3):19949. doi: http://dx.doi.org/10.7448/IAS.18.4.19949. - DOI - PMC - PubMed
    1. Cambiano V, Miners A, Phillips A. What do we know about the cost–effectiveness of HIV pre-exposure prophylaxis, and is it affordable? Curr Opin HIV AIDS. 2016;11(1):56–66. doi: http://dx.doi.org/10.1097/COH.0000000000000217. - DOI - PubMed

Substances

LinkOut - more resources